There are FDA designations, and then there’s collecting them like Pokémon. FORE Biotherapeutics just added Breakthrough Therapy Designation to plixorafenib’s résumé — joining Fast Track and Orphan Drug status — making it the first targeted therapy to earn a BTD in high-grade glioma. If you’re keeping score at home, that’s the regulatory trifecta.
And look — brain cancer doesn’t get a lot of wins. High-grade glioma is one of the cruelest diagnoses in oncology, with vanishingly few options beyond variations of temozolomide and hoping for the best. So when a small molecule oral BRAF inhibitor posts a 67% objective response rate in recurrent BRAF V600 CNS tumors across 100+ patients… you pay attention.
Plixorafenib — which FORE identified through its proprietary Foresight functional genomics platform — is what’s called a “paradox breaker.” Earlier-generation BRAF inhibitors had an annoying habit of accidentally activating the very pathway they were supposed to shut down in normal cells. Plixorafenib doesn’t do that. It hits both V600 monomers and the dimeric mutants, fusions, and splice variants that older drugs miss entirely.
Plixorafenib — The Road to Registrational
Phase 1/2a Completed
113 patients enrolled across solid tumors — 67% ORR in BRAF V600 CNS tumors, 42% ORR in rare BRAF V600 solid tumors
FDA Fast Track Designation
Granted for cancers harboring BRAF Class 1 and Class 2 alterations
FDA Orphan Drug Designation
Granted for primary brain and CNS malignancies
May 2025 — $38M Series D-2
SR One, OrbiMed, Novartis Venture Fund, Medicxi — $191M total raised
FORTE Basket Study Enrolling
Global registrational trial across multiple BRAF-mutated tumor types
April 2026 — Breakthrough Therapy Designation
First BTD granted to a targeted therapy in high-grade glioma — topline data expected end of 2026
The FORTE Basket study — FORE’s registrational trial — is currently enrolling patients across multiple BRAF-mutated tumor types, with topline monotherapy data in CNS tumors expected by the end of 2026. If those results hold up, the company has signaled it will file for accelerated approval. Which is exactly the kind of sentence that makes brain cancer patients and their families lean forward.
FORE has built a serious war chest to get here. The Philly-based company — with discovery operations in Jerusalem — closed a $38 million Series D-2 in May 2025, bringing total Series D funding to $113 million and aggregate funding to $191 million. The investor syndicate reads like a who’s who of healthcare venture: SR One, OrbiMed, Novartis Venture Fund, Medicxi, Wellington Management, and Cormorant.
Meanwhile, the competitive landscape in high-grade glioma targeted therapy remains remarkably sparse. BioLineRx recently kicked off a Phase 1/2a with an oral TET2 activator called GLIX1. Siren Biotechnology picked up a Fast Track for an AAV-based gene therapy approach. But nobody else has a targeted small molecule this deep into registrational development for HGG. FORE has the lane largely to itself — and with three FDA designations in hand, the agency clearly agrees the need is real and the early data warrants it.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
